- Home
- ACIU vs EDD Comparison
ACIU vs EDD Comparison
Compare ACIU & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EDD
- Stock Information
- Founded
- ACIU 2003
- EDD 2007
- Country
- ACIU Switzerland
- EDD United States
- Employees
- ACIU N/A
- EDD N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- ACIU Health Care
- EDD Finance
- Exchange
- ACIU Nasdaq
- EDD Nasdaq
- Market Cap
- ACIU 332.4M
- EDD 304.3M
- IPO Year
- ACIU 2016
- EDD N/A
- Fundamental
- Price
- ACIU $3.15
- EDD $4.70
- Analyst Decision
- ACIU Strong Buy
- EDD
- Analyst Count
- ACIU 2
- EDD 0
- Target Price
- ACIU $12.00
- EDD N/A
- AVG Volume (30 Days)
- ACIU 137.8K
- EDD 254.3K
- Earning Date
- ACIU 11-05-2024
- EDD 01-01-0001
- Dividend Yield
- ACIU N/A
- EDD 7.52%
- EPS Growth
- ACIU N/A
- EDD N/A
- EPS
- ACIU N/A
- EDD N/A
- Revenue
- ACIU $48,505,404.00
- EDD N/A
- Revenue This Year
- ACIU $85.33
- EDD N/A
- Revenue Next Year
- ACIU $80.69
- EDD N/A
- P/E Ratio
- ACIU N/A
- EDD N/A
- Revenue Growth
- ACIU 4097200.00
- EDD N/A
- 52 Week Low
- ACIU $2.25
- EDD $4.22
- 52 Week High
- ACIU $5.14
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- ACIU 45.92
- EDD 49.17
- Support Level
- ACIU $3.16
- EDD $4.61
- Resistance Level
- ACIU $3.48
- EDD $4.68
- Average True Range (ATR)
- ACIU 0.20
- EDD 0.05
- MACD
- ACIU -0.01
- EDD 0.01
- Stochastic Oscillator
- ACIU 6.41
- EDD 95.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.